AIDS Treatment News logo      

June 14, 2009

New hepatitis C drug may halve the length of treatment, but ribavirin still needed

"The new hepatitis C protease inhibitor drug telaprevir, when added to the standard treatment of pegylated interferon and ribavirin (IFN/RBV), achieved superior results to standard treatment, according to studies published recently in the New England Medical Journal. Furthermore it did so in 24 weeks, half the time needed for the standard regimen."

Read more in Aidsmap, June 12, 2009.